BioXcel's BXCL501 Data In Dementia Patients Reinforce Its Efficacy In Agitation

Company Plans Phase III Discussions In H1 2021

 
• By Alaric DeArment
  
Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg
BioXcel announced Phase Ib/II data for BXCL501 in demetia-related agitation. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip